Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27


C5a receptor (CD88) blockade protects against MPO-ANCA GN.

Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, Seitz LC, Penfold ME, Gan L, Hu P, Lu B, Gerard NP, Gerard C, Schall TJ, Jaen JC, Falk RJ, Jennette JC.

J Am Soc Nephrol. 2014 Feb;25(2):225-31. doi: 10.1681/ASN.2013020143. Epub 2013 Oct 31.


CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice.

Sullivan T, Miao Z, Dairaghi DJ, Krasinski A, Wang Y, Zhao BN, Baumgart T, Ertl LS, Pennell A, Seitz L, Powers J, Zhao R, Ungashe S, Wei Z, Boring L, Tsou CL, Charo I, Berahovich RD, Schall TJ, Jaen JC.

Am J Physiol Renal Physiol. 2013 Nov 1;305(9):F1288-97. doi: 10.1152/ajprenal.00316.2013. Epub 2013 Aug 28.


Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.

Sullivan TJ, Miao Z, Zhao BN, Ertl LS, Wang Y, Krasinski A, Walters MJ, Powers JP, Dairaghi DJ, Baumgart T, Seitz LC, Berahovich RD, Schall TJ, Jaen JC.

Metabolism. 2013 Nov;62(11):1623-32. doi: 10.1016/j.metabol.2013.06.008. Epub 2013 Aug 15.


1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.

Pennell AM, Aggen JB, Sen S, Chen W, Xu Y, Sullivan E, Li L, Greenman K, Charvat T, Hansen D, Dairaghi DJ, Wright JJ, Zhang P.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1228-31. doi: 10.1016/j.bmcl.2013.01.005. Epub 2013 Jan 11.


CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.

Dairaghi DJ, Oyajobi BO, Gupta A, McCluskey B, Miao S, Powers JP, Seitz LC, Wang Y, Zeng Y, Zhang P, Schall TJ, Jaen JC.

Blood. 2012 Aug 16;120(7):1449-57. doi: 10.1182/blood-2011-10-384784. Epub 2012 May 22.


Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications.

Sullivan TJ, Dairaghi DJ, Krasinski A, Miao Z, Wang Y, Zhao BN, Baumgart T, Berahovich R, Ertl LS, Pennell A, Seitz L, Miao S, Ungashe S, Wei Z, Johnson D, Boring L, Tsou CL, Charo IF, Bekker P, Schall TJ, Jaen JC.

J Pharmacol Exp Ther. 2012 Jun 5. doi: 10.1124/jpet.111.190918. Epub 2012 Jun 5. Retraction in: J Pharmacol Exp Ther. 2012 Jul;342(1):234.


Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose.

Dairaghi DJ, Zhang P, Wang Y, Seitz LC, Johnson DA, Miao S, Ertl LS, Zeng Y, Powers JP, Pennell AM, Bekker P, Schall TJ, Jaen JC.

Clin Pharmacol Ther. 2011 May;89(5):726-34. doi: 10.1038/clpt.2011.33. Epub 2011 Mar 30.


Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.

Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, Dairaghi DJ, Bekker P, Ertl LS, Penfold ME, Jaen JC, Keshav S, Wendt E, Pennell A, Ungashe S, Wei Z, Wright JJ, Schall TJ.

J Pharmacol Exp Ther. 2010 Oct;335(1):61-9. doi: 10.1124/jpet.110.169714. Epub 2010 Jul 21.


CXCR3 antagonism impairs the development of donor-reactive, IFN-gamma-producing effectors and prolongs allograft survival.

Rosenblum JM, Zhang QW, Siu G, Collins TL, Sullivan T, Dairaghi DJ, Medina JC, Fairchild RL.

Transplantation. 2009 Feb 15;87(3):360-9. doi: 10.1097/TP.0b013e31819574e9.


Optimization of 2-aminothiazole derivatives as CCR4 antagonists.

Wang X, Xu F, Xu Q, Mahmud H, Houze J, Zhu L, Akerman M, Tonn G, Tang L, McMaster BE, Dairaghi DJ, Schall TJ, Collins TL, Medina JC.

Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. Epub 2006 Feb 23.


Characterization of the rhesus cytomegalovirus US28 locus.

Penfold ME, Schmidt TL, Dairaghi DJ, Barry PA, Schall TJ.

J Virol. 2003 Oct;77(19):10404-13.


Comprehensive mapping of poxvirus vCCI chemokine-binding protein. Expanded range of ligand interactions and unusual dissociation kinetics.

Burns JM, Dairaghi DJ, Deitz M, Tsang M, Schall TJ.

J Biol Chem. 2002 Jan 25;277(4):2785-9. Epub 2001 Nov 5.


Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK.

Gosling J, Dairaghi DJ, Wang Y, Hanley M, Talbot D, Miao Z, Schall TJ.

J Immunol. 2000 Mar 15;164(6):2851-6.


Cytomegalovirus-encoded beta chemokine promotes monocyte-associated viremia in the host.

Saederup N, Lin YC, Dairaghi DJ, Schall TJ, Mocarski ES.

Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10881-6.


Cytomegalovirus encodes a potent alpha chemokine.

Penfold ME, Dairaghi DJ, Duke GM, Saederup N, Mocarski ES, Kemble GW, Schall TJ.

Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9839-44.


HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines.

Dairaghi DJ, Fan RA, McMaster BE, Hanley MR, Schall TJ.

J Biol Chem. 1999 Jul 30;274(31):21569-74.


Human thymocytes express CCR-3 and are activated by eotaxin.

Franz-Bacon K, Dairaghi DJ, Boehme SA, Sullivan SK, Schall TJ, Conlon PJ, Taylor N, Bacon KB.

Blood. 1999 May 15;93(10):3233-40.


Neuronal expression of fractalkine in the presence and absence of inflammation.

Schwaeble WJ, Stover CM, Schall TJ, Dairaghi DJ, Trinder PK, Linington C, Iglesias A, Schubart A, Lynch NJ, Weihe E, Schäfer MK.

FEBS Lett. 1998 Nov 20;439(3):203-7.


Macrophage inflammatory protein-1beta induces migration and activation of human thymocytes.

Dairaghi DJ, Franz-Bacon K, Callas E, Cupp J, Schall TJ, Tamraz SA, Boehme SA, Taylor N, Bacon KB.

Blood. 1998 Apr 15;91(8):2905-13.


RANTES-induced T cell activation correlates with CD3 expression.

Dairaghi DJ, Soo KS, Oldham ER, Premack BA, Kitamura T, Bacon KB, Schall TJ.

J Immunol. 1998 Jan 1;160(1):426-33.


Chemokine receptor CCR3 function is highly dependent on local pH and ionic strength.

Dairaghi DJ, Oldham ER, Bacon KB, Schall TJ.

J Biol Chem. 1997 Nov 7;272(45):28206-9.


CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells.

Greaves DR, Wang W, Dairaghi DJ, Dieu MC, Saint-Vis B, Franz-Bacon K, Rossi D, Caux C, McClanahan T, Gordon S, Zlotnik A, Schall TJ.

J Exp Med. 1997 Sep 15;186(6):837-44.


Human mitochondrial transcription factor A and promoter spacing integrity are required for transcription initiation.

Dairaghi DJ, Shadel GS, Clayton DA.

Biochim Biophys Acta. 1995 May 24;1271(1):127-34.


Secondary structure of RNase MRP RNA as predicted by phylogenetic comparison.

Schmitt ME, Bennett JL, Dairaghi DJ, Clayton DA.

FASEB J. 1993 Jan;7(1):208-13.


Supplemental Content

Loading ...
Support Center